ACE Inhibitors and Diuretics — Competitive Intelligence Brief

ACE Inhibitors and Diuretics (ACE Inhibitors and Diuretics) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor + diuretic combination. Area: Cardiovascular.

marketed ACE inhibitor + diuretic combination Angiotensin-converting enzyme (ACE); various diuretic targets depending on class (e.g., loop of Henle, distal convoluted tubule) Cardiovascular Small molecule

Target snapshot

ACE Inhibitors and Diuretics (ACE Inhibitors and Diuretics) — The University of Texas Health Science Center, Houston. ACE inhibitors block angiotensin-converting enzyme to reduce angiotensin II production and lower blood pressure, while diuretics increase sodium and water excretion to reduce fluid volume and blood pressure.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ACE Inhibitors and Diuretics TARGET	ACE Inhibitors and Diuretics	The University of Texas Health Science Center, Houston	marketed	ACE inhibitor + diuretic combination	Angiotensin-converting enzyme (ACE); various diuretic targets depending on class (e.g., loop of Henle, distal convoluted tubule)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor + diuretic combination class)

1. The University of Texas Health Science Center, Houston · 1 drug in this class